The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial.
 
Paula Rodríguez-Otero
Honoraria - Abbvie; Celgene; GlaxoSmithKline; H3 Biomedicine; Janssen; Pfizer; Regeneron; Roche/Genentech; Sanofi
Consulting or Advisory Role - Abbvie; BMS; GlaxoSmithKline; Janssen; Pfizer; Roche; Sanofi
Speakers' Bureau - BMS; GlaxoSmithKline; Janssen; Sanofi
Travel, Accommodations, Expenses - Pfizer
 
Sosana Delimpasi
Speakers' Bureau - GlaxoSmithKline; Johnson & Johnson; Takeda
 
Albert Oriol
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Pfizer; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Sanofi
 
Meletios Dimopoulos
Honoraria - Amgen; AstraZeneca; Beigene; Bristol-Myers Squibb; GlaxoSmithKline; Janssen-Cilag; Menarini; Regeneron; Sanofi; Swixx BioPharma; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Beigene; Bristol-Myers Squibb; GlaxoSmithKline; Janssen-Cilag; Menarini; Regeneron; Sanofi; Swixx BioPharma; Takeda
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb/Celgene; Janssen; Takeda
 
Xavier Leleu
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; GlaxoSmithKline; Janssen-Cilag; Novartis; Oncopeptides; Roche; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Janssen-Cilag; Novartis; Roche; Takeda
Travel, Accommodations, Expenses - Takeda
 
Salomon Manier
Consulting or Advisory Role - Adaptive Biotechnologies (Inst); Amgen (Inst); Celgene/Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst)
 
Carmen Martinez-Chamorro
Honoraria - Abbvie; Amgen; BMS GmbH & Co. KG; Janssen Biologics BV
Consulting or Advisory Role - Abbvie; BeiGene; Janssen
Travel, Accommodations, Expenses - Janssen
 
Rajshekhar Chakraborty
Honoraria - Guidepoint Global
Consulting or Advisory Role - Adaptive Biotechnologies; Janssen; Sanofi Pasteur
Research Funding - Genentech (Inst)
 
Sam Rubinstein
Honoraria - Sanofi
Consulting or Advisory Role - Janssen; LAVA Therapeutics
 
Anna Sureda
Honoraria - Alexion Pharmaceuticals; Amgen; Bristol-Myers Squibb/Celgene; Janssen; Kite/Gilead; MSD; Novartis; Roche; Sanofi; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Gilead Sciences; Janssen; Novartis; Sanofi; Takeda
Speakers' Bureau - Takeda
Research Funding - Bristol-Myers Squibb/Celgene; Takeda
Travel, Accommodations, Expenses - Kite/Gilead; Takeda
 
Marta Sonia Gonzalez
Consulting or Advisory Role - Amgen; Janssen Oncology; Menarini; Pfizer; Sanofi
Speakers' Bureau - Janssen Oncology
Travel, Accommodations, Expenses - Janssen Oncology; Pfizer; Sanofi
 
Jean-Marie Michot
Consulting or Advisory Role - Bristol-Myers Squibb; IDEOGEN; Mallinckrodt/Therakos; Regeneron
Research Funding - Astex Pharmaceuticals (Inst); GlaxoSmithKline (Inst)
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - Cellgen
 
Aurora Breazna
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Research Funding - Regeneron
Travel, Accommodations, Expenses - Regeneron
 
James Drew
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Research Funding - Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Anita Boyapati
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - US20230059376A1 Methods and compositions for treating subjects having rheumatoid arthritis PCT/US2023/073225 METHODS OF TREATING NON-SMALL CELL LUNG CANCER USING MESENCHYMAL EPITHELIAL TRANSITION FACTOR (MET)-TARGETED AGENTS
 
Sheila Masinde
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Glenn Kroog
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Research Funding - Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Shawn Sarkaria
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Research Funding - Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Joaquin Martinez-Lopez
Consulting or Advisory Role - BMS GmbH & Co. KG; Gilead Sciences; Janssen; Novartis; Roche